Hospital
Capital Health System, INC.
Capital Health System, INC. was paid $132.16M by Medicaid between Jan 2018 and Dec 2024, across 350 billing codes. Its largest line is 99283, emergency room visit (moderate) — 22% of everything it billed.
33Billing provider infoCAPITAL HEALTH SYSTEM, INC.
PENNINGTON, NJ 08534
PENNINGTON, NJ 08534
33aNPI1073516183assigned 05/23/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$132.16M
24GClaims1,264,718
24DCodes billed350
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in New Jersey
Rank by total paid#14 of 93
Median peer was paid$30.60M
This provider vs. median4.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 123,805 | $18.30M | |
| 2019 | 139,266 | $17.43M | |
| 2020 | 139,174 | $14.34M | |
| 2021 | 194,276 | $19.71M | |
| 2022 | 239,519 | $22.06M | |
| 2023 | 248,103 | $22.27M | |
| 2024incomplete | 180,575 | $18.06M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 22% | 71,060 | 66,872 | $29.08M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 51,876 | 48,036 | $19.48M |
| G0378 | Hospital observation service, per hour | 9.6% | 11,427 | 9,257 | $12.71M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 5.6% | 22,381 | 21,459 | $7.34M |
| 59025 | Fetal non-stress test | 4.8% | 8,226 | 3,541 | $6.32M |
| 41899 | Unlisted procedure, dentoalveolar structures | 4.1% | 1,448 | 1,442 | $5.35M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.4% | 13,720 | 12,654 | $4.53M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 3.4% | 5,319 | 5,120 | $4.49M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 3.0% | 1,800 | 1,732 | $4.02M |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | 1.7% | 2,877 | 2,854 | $2.28M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.4% | 6,126 | 5,897 | $1.87M |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 1.1% | 1,001 | 963 | $1.52M |
338 more codes
| 93017 | 1.1% | 2,831 | $1.51M | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 921 | $1.24M |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 4,659 | $1.23M |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 5,376 | $1.05M |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 502 | $943K |
| 76801 | <1% | 3,658 | $858K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 17,585 | $818K |
| 76830 | Ultrasound, transvaginal | <1% | 2,879 | $801K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 1,269 | $785K |
| OP250 | <1% | 39,482 | $753K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 6,202 | $749K |
| OP379 | <1% | 12,416 | $689K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 3,794 | $658K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 5,734 | $640K |
| 93970 | <1% | 1,508 | $610K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 25,229 | $593K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 13,823 | $589K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 707 | $578K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,862 | $540K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,423 | $504K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 4,863 | $494K |
| OP272 | <1% | 26,263 | $457K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 3,316 | $429K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,390 | $420K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 966 | $420K |
| 93971 | <1% | 1,864 | $414K | |
| 80053 | Comprehensive metabolic panel | <1% | 39,889 | $412K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 349 | $402K |
| 95811 | <1% | 369 | $386K | |
| 76818 | <1% | 880 | $381K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 11,354 | $378K |
| 77066 | Tomosynthesis, mammo | <1% | 1,042 | $354K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 12,446 | $340K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 334 | $337K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 50,586 | $332K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,748 | $324K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 22,828 | $296K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 10,479 | $291K |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 539 | $289K |
| 36415 | Collection of venous blood by venipuncture | <1% | 54,543 | $287K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 16,057 | $274K |
| 77080 | <1% | 1,433 | $260K | |
| 76536 | <1% | 1,223 | $254K | |
| 76813 | <1% | 1,137 | $250K | |
| 71250 | <1% | 1,023 | $244K | |
| 76642 | <1% | 1,846 | $241K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 25,208 | $239K |
| OP258 | <1% | 37,555 | $231K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 893 | $220K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 2,237 | $212K |
| 73564 | <1% | 2,108 | $185K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,484 | $177K |
| 73130 | <1% | 2,507 | $174K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 23,038 | $162K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,108 | $156K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 11,177 | $146K |
| 96415 | <1% | 1,026 | $144K | |
| 73610 | <1% | 2,610 | $138K | |
| 72110 | <1% | 798 | $134K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 3,582 | $134K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 261 | $130K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,206 | $124K |
| 93226 | <1% | 307 | $123K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 4,607 | $120K |
| 73630 | <1% | 2,860 | $120K | |
| 73030 | <1% | 1,942 | $114K | |
| 96417 | <1% | 554 | $104K | |
| 76641 | <1% | 209 | $101K | |
| 76820 | <1% | 589 | $94K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,751 | $92K |
| 87070 | <1% | 9,998 | $92K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 3,208 | $91K |
| 64483 | <1% | 38 | $90K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 280 | $88K |
| 77065 | Tomosynthesis, mammo | <1% | 380 | $86K |
| 86850 | <1% | 7,446 | $85K | |
| 93225 | <1% | 306 | $84K | |
| 71045 | Radiologic examination, chest; single view | <1% | 11,646 | $82K |
| 92587 | <1% | 172 | $78K | |
| J3490 | Unclassified drugs | <1% | 11,318 | $76K |
| 73110 | <1% | 1,416 | $71K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 15,744 | $71K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 39 | $68K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 7,928 | $68K |
| 94729 | <1% | 837 | $64K | |
| 73502 | <1% | 932 | $63K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,239 | $62K |
| 72100 | <1% | 650 | $61K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,678 | $59K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 960 | $59K |
| 88342 | <1% | 2,609 | $59K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,859 | $58K |
| 82948 | <1% | 13,763 | $57K | |
| 95886 | <1% | 286 | $56K | |
| 74018 | <1% | 1,745 | $55K | |
| 97161 | <1% | 1,478 | $54K | |
| OP271 | <1% | 2,030 | $53K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 1,594 | $53K |
| 81001 | <1% | 31,871 | $52K | |
| J2704 | Injection, propofol, 10 mg | <1% | 8,702 | $50K |
| 96411 | <1% | 243 | $50K | |
| 93458 | <1% | 14 | $49K | |
| 94375 | <1% | 743 | $49K | |
| 84484 | <1% | 14,533 | $48K | |
| 94060 | <1% | 75 | $47K | |
| 76775 | <1% | 346 | $45K | |
| 94726 | <1% | 678 | $45K | |
| 94664 | <1% | 731 | $44K | |
| 93270 | <1% | 319 | $43K | |
| 73562 | <1% | 1,022 | $42K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 7,492 | $41K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 3,603 | $41K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 471 | $41K |
| 87400 | <1% | 2,992 | $41K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 1,316 | $39K |
| 94200 | <1% | 639 | $39K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 3,366 | $38K |
| OP270 | <1% | 6,986 | $38K | |
| 93923 | <1% | 138 | $37K | |
| 85027 | <1% | 15,253 | $36K | |
| 86900 | <1% | 7,769 | $36K | |
| 97164 | <1% | 768 | $34K | |
| 94760 | <1% | 2,516 | $32K | |
| 85610 | <1% | 16,932 | $30K | |
| 76937 | <1% | 711 | $30K | |
| 88341 | <1% | 562 | $29K | |
| 87077 | <1% | 5,403 | $29K | |
| 77412 | <1% | 116 | $28K | |
| 85730 | <1% | 15,142 | $28K | |
| 96367 | <1% | 1,480 | $28K | |
| 84702 | <1% | 5,090 | $28K | |
| 73590 | <1% | 387 | $27K | |
| 73090 | <1% | 434 | $26K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 11,497 | $26K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 403 | $25K |
| 97162 | <1% | 921 | $25K | |
| 77336 | <1% | 130 | $24K | |
| 83880 | <1% | 3,907 | $24K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 84 | $23K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,509 | $23K |
| 83690 | <1% | 13,263 | $23K | |
| 87480 | <1% | 3,114 | $23K | |
| 73080 | <1% | 436 | $21K | |
| 96376 | <1% | 2,648 | $21K | |
| 87040 | <1% | 4,228 | $20K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 678 | $20K |
| 76870 | <1% | 205 | $20K | |
| 70486 | <1% | 136 | $20K | |
| 86901 | <1% | 7,791 | $20K | |
| 36591 | <1% | 2,211 | $20K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 4,179 | $19K |
| 81003 | <1% | 5,489 | $19K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 17,531 | $19K |
| 12011 | <1% | 426 | $18K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 287 | $18K |
| 87660 | <1% | 3,114 | $18K | |
| 87510 | <1% | 3,115 | $17K | |
| 12001 | <1% | 459 | $17K | |
| 82248 | <1% | 3,239 | $17K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,864 | $16K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 4,621 | $16K |
| 64635 | <1% | 15 | $16K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,753 | $16K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 10,891 | $16K |
| 72131 | <1% | 96 | $16K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 6,480 | $16K |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | <1% | 96 | $15K |
| 95806 | <1% | 98 | $15K | |
| 73140 | <1% | 651 | $15K | |
| 83735 | <1% | 8,142 | $14K | |
| 87186 | <1% | 3,790 | $14K | |
| 85007 | <1% | 8,382 | $13K | |
| 85379 | <1% | 3,108 | $13K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 3,209 | $12K |
| 93880 | <1% | 56 | $12K | |
| 83605 | <1% | 3,277 | $12K | |
| 76821 | <1% | 28 | $12K | |
| 92523 | <1% | 221 | $12K | |
| 74019 | <1% | 445 | $11K | |
| 80076 | <1% | 3,174 | $11K | |
| 88304 | <1% | 577 | $11K | |
| 82247 | <1% | 2,945 | $10K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 123 | $10K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 203 | $10K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 5,453 | $10K |
| 86140 | <1% | 3,426 | $9K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 79 | $9K |
| 72141 | <1% | 15 | $9K | |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 421 | $8K |
| 97165 | <1% | 358 | $8K | |
| 97010 | <1% | 4,777 | $8K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,684 | $8K |
| OP278 | <1% | 140 | $8K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,079 | $8K |
| 87507 | <1% | 129 | $7K | |
| 71271 | <1% | 59 | $7K | |
| 29125 | <1% | 482 | $7K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 2,093 | $7K |
| OP279 | <1% | 4,336 | $7K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,196 | $7K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 67 | $7K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 316 | $7K |
| 76770 | <1% | 29 | $7K | |
| 87807 | <1% | 618 | $7K | |
| C1769 | Guide wire | <1% | 1,068 | $6K |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 1,083 | $6K |
| 72114 | <1% | 26 | $6K | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 723 | $6K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 5,908 | $6K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,507 | $6K |
| 80061 | Lipid panel | <1% | 1,167 | $5K |
| 92550 | <1% | 71 | $5K | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 270 | $5K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 2,640 | $5K |
| 10060 | <1% | 167 | $5K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 447 | $5K |
| 96368 | <1% | 238 | $4K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 302 | $4K |
| 29540 | <1% | 492 | $4K | |
| 90715 | <1% | 996 | $4K | |
| 72040 | <1% | 59 | $4K | |
| 81002 | <1% | 3,541 | $3K | |
| 70491 | <1% | 12 | $3K | |
| 84703 | <1% | 2,438 | $3K | |
| 82550 | <1% | 1,936 | $3K | |
| 84439 | <1% | 1,101 | $3K | |
| 64636 | <1% | 15 | $3K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 25 | $3K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,752 | $3K |
| 84550 | <1% | 778 | $2K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 297 | $2K |
| 95816 | <1% | 12 | $2K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 26 | $2K |
| 51701 | <1% | 289 | $2K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,302 | $2K |
| 84132 | <1% | 654 | $2K | |
| 36416 | <1% | 1,488 | $2K | |
| 87205 | <1% | 940 | $2K | |
| 97116 | <1% | 777 | $2K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 787 | $2K |
| 86803 | <1% | 137 | $2K | |
| 84145 | <1% | 413 | $2K | |
| 72082 | <1% | 12 | $2K | |
| 82728 | <1% | 392 | $2K | |
| 85651 | <1% | 1,522 | $2K | |
| J0461 | Injection, atropine sulfate, 0.01 mg | <1% | 292 | $2K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 13 | $2K |
| 84100 | <1% | 1,526 | $1K | |
| 88307 | <1% | 98 | $1K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 557 | $1K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 262 | $1K |
| 82805 | <1% | 245 | $1K | |
| 73552 | <1% | 38 | $1K | |
| 83615 | <1% | 915 | $1K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 59 | $1K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 1,939 | $1K |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | <1% | 13 | $1K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 108 | $959.95 |
| 82378 | <1% | 186 | $924.58 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 4,349 | $913.16 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 259 | $891.48 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 730 | $854.55 |
| 92588 | <1% | 12 | $848.48 | |
| 29130 | <1% | 50 | $802.78 | |
| 82570 | <1% | 1,122 | $738.94 | |
| OP229 | <1% | 13 | $667.29 | |
| 29530 | <1% | 79 | $662.89 | |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 48 | $659.87 |
| J7999 | Compounded drug, not otherwise classified | <1% | 817 | $644.35 |
| 29515 | <1% | 104 | $550.12 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 331 | $524.67 |
| 81025 | <1% | 324 | $495.21 | |
| 36430 | <1% | 13 | $454.18 | |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 15 | $450.00 |
| 94761 | <1% | 181 | $431.43 | |
| 86480 | <1% | 12 | $431.34 | |
| 82731 | <1% | 27 | $409.40 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 73 | $397.07 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 431 | $395.04 |
| A4648 | Tissue marker, implantable, any type, each | <1% | 44 | $388.28 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 244 | $383.03 |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 37 | $379.96 |
| 86923 | <1% | 28 | $372.09 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 29 | $361.18 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 611 | $358.57 |
| 84156 | <1% | 864 | $347.41 | |
| J1094 | Injection, dexamethasone acetate, 1 mg | <1% | 56 | $330.50 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 70 | $320.14 |
| 85014 | <1% | 765 | $318.07 | |
| 74022 | <1% | 27 | $313.31 | |
| 74021 | <1% | 72 | $287.07 | |
| 97166 | <1% | 49 | $258.67 | |
| 83021 | <1% | 13 | $249.40 | |
| C1758 | Catheter, ureteral | <1% | 261 | $219.36 |
| 87340 | <1% | 50 | $215.16 | |
| 86308 | <1% | 37 | $214.15 | |
| J2791 | Injection, rho(d) immune globulin (human), (rhophylac), intramuscular or intravenous, 100 iu | <1% | 12 | $199.32 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 103 | $195.15 |
| G0432 | Infectious agent antibody detection by enzyme immunoassay (eia) technique, hiv-1 and/or hiv-2, screening | <1% | 30 | $191.14 |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 27 | $186.85 |
| 85384 | <1% | 71 | $178.60 | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 55 | $175.95 |
| 82565 | <1% | 211 | $168.05 | |
| 86592 | <1% | 412 | $166.99 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 40 | $163.32 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 432 | $150.43 |
| C1726 | Catheter, balloon dilatation, non-vascular | <1% | 16 | $147.87 |
| 85018 | <1% | 130 | $145.44 | |
| 82607 | <1% | 43 | $142.24 | |
| 82803 | <1% | 41 | $141.40 | |
| 83540 | <1% | 159 | $135.45 | |
| 73660 | <1% | 12 | $117.58 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 320 | $95.00 |
| 83550 | <1% | 96 | $93.12 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 158 | $75.99 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 88 | $67.16 |
| J0692 | Injection, cefepime hydrochloride, 500 mg | <1% | 45 | $57.12 |
| C1729 | Catheter, drainage | <1% | 42 | $56.71 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 252 | $53.07 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 16 | $45.25 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 38 | $41.73 |
| 82150 | <1% | 21 | $41.21 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 29 | $37.95 |
| 85045 | <1% | 45 | $34.40 | |
| 84295 | <1% | 70 | $25.32 | |
| 86762 | <1% | 13 | $19.20 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 14 | $15.74 |
| 84450 | <1% | 13 | $15.00 | |
| 84460 | <1% | 13 | $15.00 | |
| J0694 | Injection, cefoxitin sodium, 1 gm | <1% | 14 | $11.84 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 12 | $9.01 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 15 | $6.57 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 26 | $6.25 |
| Q0245 | Injection, bamlanivimab and etesevimab, 2100 mg | <1% | 22 | $6.00 |
| Q0222 | Injection, bebtelovimab, 175 mg | <1% | 13 | $2.00 |
| Q0247 | Injection, sotrovimab, 500 mg | <1% | 16 | $1.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 284 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialVISCONTI, DEBORAH (DIRECTOR OF PATIENT ACCOUNTS)
| Provider | Location | Paid |
|---|---|---|
| Capital Health System INC | Trenton, NJ | $114.53M |
| Capital Health System INC | Trenton, NJ | $6.14M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.